Chembio Diagnostics (CEMI) 3.96 $CEMI
Chembio Diagnostics wins approval in Brazil for commercial use of DPP HIV-Syphilis combination assay
M2 - Tue Feb 10, 5:17AM CST
Diagnostic test company Chembio Diagnostics (NasdaqCM:CEMI) disclosed on Monday the receipt of approval from the Brazilian regulatory agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA) for the commercial use of its DPP HIV-Syphilis Assay.
CEMI: 3.96 (-0.04)
Chembio's DPP(R) HIV-Syphilis Assay Cleared for Launch in Brazil
GlobeNewswire - Mon Feb 09, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has received approval for commercial use of its DPP HIV-Syphilis Assay by the Brazilian regulatory agency, Agencia Nacional de Vigilancia Sanitária (ANVISA). The Chembio Dual Path Platform (DPP) HIV-Syphilis Assay is the only POC test cleared for commercialization in Brazil for rapid, POC detection of both HIV 1/2 and syphilis. Chembio developed this novel combination assay to address the growing concern among public health officials regarding co-infection rates of HIV and syphilis as well as mother-to-child transmission (MTCT) of HIV and syphilis.
CEMI: 3.96 (-0.04)
Chembio Awarded Grant to Develop Next-Generation Point-of-Care Diagnostic Test for Malaria
GlobeNewswire - Thu Jan 29, 9:03AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has been awarded a grant from the Bill & Melinda Gates Foundation to expedite the feasibility testing and development of a DPP Malaria POC rapid diagnostic to accurately identify individuals infected with Plasmodium falciparum parasite.
CEMI: 3.96 (-0.04)
Chembio to purchase 100% rights to SURE CHECK HIV 1/2 Assay
M2 - Fri Jan 23, 8:01PM CST
Diagnostic tests company Chembio Diagnostics (NasdaqCM:CEMI) on Thursday announced an agreement to acquire the rights to the SURE CHECK HIV 1/2 Assay from StatSure Diagnostic Systems (SDS).
CEMI: 3.96 (-0.04)
Chembio Acquires Rights to SURE CHECK(R) HIV 1/2 Assay Effective June 1, 2016
GlobeNewswire - Thu Jan 22, 9:03AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has entered into an agreement with StatSure Diagnostic Systems, Inc. (SDS) to acquire SDS' interest in the SURE CHECK HIV 1/2 Assay, effective June 1, 2016.
ALR: 43.40 (-0.40), CEMI: 3.96 (-0.04)
Chembio to own full rights to HIV 1/2 test by mid-2016
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:59AM CST
ALR: 43.40 (-0.40), CEMI: 3.96 (-0.04)
Chembio Update on DPP(R) Ebola and DPP(R) Febrile Illness Assays
GlobeNewswire - Mon Jan 12, 8:16AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced its progress in the development of DPP Ebola and DPP Febrile Illness Assays.
CEMI: 3.96 (-0.04)
Chembio Appoints Paul Lambotte as Vice President, Product Development
GlobeNewswire - Thu Jan 08, 7:50AM CST
Chembio Diagnostics Systems, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced the appointment of Paul Lambotte, Ph.D., as Vice President, Product Development.
CEMI: 3.96 (-0.04)
Chembio Diagnostics to Present at the Biotech Showcase 2015 Conference
GlobeNewswire - Wed Jan 07, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced that its chief executive officer, John J. Sperzel III, will present a corporate update at the 7 Annual Biotech Showcase Conference in San Francisco, CA. The Biotech Showcase Conference will take place January 12-14, 2015 at the Parc 55 Wyndham Union Square Hotel.
CEMI: 3.96 (-0.04)
Chembio DPP(R) Technology to be Used in Development of Point-of-Care Diagnostic Test for Traumatic Brain Injury and Sports-Related Concussion
GlobeNewswire - Tue Jan 06, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into an agreement with the Concussion Science Group (CSG) Division of Perseus Science Group LLC, to utilize Chembio's patented DPP technology to develop a POC diagnostic test for traumatic brain injury (TBI), including sports-related concussion.
CEMI: 3.96 (-0.04)
Chembio to develop multiplex Point-of-Care Test for Influenza Immunity in partnership with the US CDC
M2 - Tue Nov 25, 8:50AM CST
Diagnostic tests company Chembio Diagnostics (NasdaqCM:CEMI) on Monday reported a follow-on, milestone-based development agreement for a multiplex POC influenza immunity test utilising its patented Dual Path Platform (DPP) technology in partnership with an undisclosed company and the US Centers for Disease Control and Prevention (CDC).
CEMI: 3.96 (-0.04)
Chembio Signs Agreement With CDC Contractor to Develop a Multiplex Point-of-Care Test for Influenza Immunity
GlobeNewswire - Mon Nov 24, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into a follow-on, milestone-based development agreement with a private contracting organization acting on behalf of the United States Centers for Disease Control and Prevention (CDC), for a multiplex POC influenza immunity test utilizing Chembio's patented Dual Path Platform (DPP) technology.
CEMI: 3.96 (-0.04)
Cepheid receives grant to develop Ebola test
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 7:11AM CST
CPHD: 59.62 (+0.72), CEMI: 3.96 (-0.04)
Chembio Diagnostics' (CEMI) CEO John Sperzel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 11:04AM CST
CEMI: 3.96 (-0.04)
Chembio Diagnostics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:56AM CST
CEMI: 3.96 (-0.04)
Chembio Diagnostics Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the third quarter and nine months ended September 30, 2014.
CEMI: 3.96 (-0.04)
Chembio Diagnostics wins approval in Brazil for commercial use of DPP HIV-Syphilis combination assay
M2 - Tue Feb 10, 5:17AM CST
Diagnostic test company Chembio Diagnostics (NasdaqCM:CEMI) disclosed on Monday the receipt of approval from the Brazilian regulatory agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA) for the commercial use of its DPP HIV-Syphilis Assay.
CEMI: 3.96 (-0.04)
Chembio's DPP(R) HIV-Syphilis Assay Cleared for Launch in Brazil
GlobeNewswire - Mon Feb 09, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has received approval for commercial use of its DPP HIV-Syphilis Assay by the Brazilian regulatory agency, Agencia Nacional de Vigilancia Sanitária (ANVISA). The Chembio Dual Path Platform (DPP) HIV-Syphilis Assay is the only POC test cleared for commercialization in Brazil for rapid, POC detection of both HIV 1/2 and syphilis. Chembio developed this novel combination assay to address the growing concern among public health officials regarding co-infection rates of HIV and syphilis as well as mother-to-child transmission (MTCT) of HIV and syphilis.
CEMI: 3.96 (-0.04)
Chembio Awarded Grant to Develop Next-Generation Point-of-Care Diagnostic Test for Malaria
GlobeNewswire - Thu Jan 29, 9:03AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has been awarded a grant from the Bill & Melinda Gates Foundation to expedite the feasibility testing and development of a DPP Malaria POC rapid diagnostic to accurately identify individuals infected with Plasmodium falciparum parasite.
CEMI: 3.96 (-0.04)
Chembio to purchase 100% rights to SURE CHECK HIV 1/2 Assay
M2 - Fri Jan 23, 8:01PM CST
Diagnostic tests company Chembio Diagnostics (NasdaqCM:CEMI) on Thursday announced an agreement to acquire the rights to the SURE CHECK HIV 1/2 Assay from StatSure Diagnostic Systems (SDS).
CEMI: 3.96 (-0.04)
Chembio Acquires Rights to SURE CHECK(R) HIV 1/2 Assay Effective June 1, 2016
GlobeNewswire - Thu Jan 22, 9:03AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has entered into an agreement with StatSure Diagnostic Systems, Inc. (SDS) to acquire SDS' interest in the SURE CHECK HIV 1/2 Assay, effective June 1, 2016.
ALR: 43.40 (-0.40), CEMI: 3.96 (-0.04)
Chembio to own full rights to HIV 1/2 test by mid-2016
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 8:59AM CST
ALR: 43.40 (-0.40), CEMI: 3.96 (-0.04)
Chembio Update on DPP(R) Ebola and DPP(R) Febrile Illness Assays
GlobeNewswire - Mon Jan 12, 8:16AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced its progress in the development of DPP Ebola and DPP Febrile Illness Assays.
CEMI: 3.96 (-0.04)
Chembio Appoints Paul Lambotte as Vice President, Product Development
GlobeNewswire - Thu Jan 08, 7:50AM CST
Chembio Diagnostics Systems, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced the appointment of Paul Lambotte, Ph.D., as Vice President, Product Development.
CEMI: 3.96 (-0.04)
Chembio Diagnostics to Present at the Biotech Showcase 2015 Conference
GlobeNewswire - Wed Jan 07, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced that its chief executive officer, John J. Sperzel III, will present a corporate update at the 7 Annual Biotech Showcase Conference in San Francisco, CA. The Biotech Showcase Conference will take place January 12-14, 2015 at the Parc 55 Wyndham Union Square Hotel.
CEMI: 3.96 (-0.04)
Chembio DPP(R) Technology to be Used in Development of Point-of-Care Diagnostic Test for Traumatic Brain Injury and Sports-Related Concussion
GlobeNewswire - Tue Jan 06, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into an agreement with the Concussion Science Group (CSG) Division of Perseus Science Group LLC, to utilize Chembio's patented DPP technology to develop a POC diagnostic test for traumatic brain injury (TBI), including sports-related concussion.
CEMI: 3.96 (-0.04)
Chembio to develop multiplex Point-of-Care Test for Influenza Immunity in partnership with the US CDC
M2 - Tue Nov 25, 8:50AM CST
Diagnostic tests company Chembio Diagnostics (NasdaqCM:CEMI) on Monday reported a follow-on, milestone-based development agreement for a multiplex POC influenza immunity test utilising its patented Dual Path Platform (DPP) technology in partnership with an undisclosed company and the US Centers for Disease Control and Prevention (CDC).
CEMI: 3.96 (-0.04)
Chembio Signs Agreement With CDC Contractor to Develop a Multiplex Point-of-Care Test for Influenza Immunity
GlobeNewswire - Mon Nov 24, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered into a follow-on, milestone-based development agreement with a private contracting organization acting on behalf of the United States Centers for Disease Control and Prevention (CDC), for a multiplex POC influenza immunity test utilizing Chembio's patented Dual Path Platform (DPP) technology.
CEMI: 3.96 (-0.04)
Cepheid receives grant to develop Ebola test
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 7:11AM CST
CPHD: 59.62 (+0.72), CEMI: 3.96 (-0.04)
Chembio Diagnostics' (CEMI) CEO John Sperzel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 11:04AM CST
CEMI: 3.96 (-0.04)
Chembio Diagnostics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:56AM CST
CEMI: 3.96 (-0.04)
Chembio Diagnostics Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the third quarter and nine months ended September 30, 2014.
CEMI: 3.96 (-0.04)
